Comparative Pharmacology
Head-to-head clinical analysis: MEPERIDINE AND ATROPINE SULFATE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERIDINE AND ATROPINE SULFATE versus METHADOSE.
MEPERIDINE AND ATROPINE SULFATE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist primarily at mu-opioid receptors, producing analgesia; atropine is a competitive antagonist of muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretions.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
1-2 mL (meperidine 50 mg/mL + atropine 0.4 mg/mL) IM or IV push (over 2-3 minutes) every 3-4 hours as needed.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Meperidine: Terminal half-life 3-4 hours (normal renal function), prolonged in hepatic disease (up to 7-10 hours) and renal impairment (normeperidine accumulates). Atropine: Terminal half-life 2-4 hours.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Meperidine: Renal excretion of unchanged drug (~5-10%) and metabolites, primarily normeperidine (active), with <5% biliary/fecal. Atropine: Renal excretion (~30-50% unchanged), remainder as metabolites, minimal biliary/fecal.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist